Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sophy Inc. is active in the Biotechnology & Pharmaceuticals technology area. The company's prosecution profile currently includes 1 pending office action. This action is assigned to 1 distinct examiner, suggesting a highly targeted approach to securing patents in this field. Such a narrow distribution often indicates a very specific technological focus or a nascent stage of portfolio development within the United States patent system.
The busiest examiner for Sophy Inc. is HIBSHMAN, SARAH GRACE, who is currently managing 1 pending office action. The fact that only 1 distinct art unit is involved indicates that the company's active filings fall within a specific technical niche. This concentration means there is no opportunity to compare different examiner behaviors or art unit standards within the company's current workload, requiring a strategy tailored to a single set of expectations.
All strategic decisions must be focused on the 1 distinct art unit, making the outcome of the 1 pending office action a critical indicator of progress. Practitioners should note that HIBSHMAN, SARAH GRACE is the sole official determining the immediate trajectory of the portfolio. This streamlined data set reflects a period of focused prosecution activity where the technical nuances of Biotechnology & Pharmaceuticals are handled by a single point of contact at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HIBSHMAN, SARAH GRACE | 1 | 38.9% | +40.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001994 | BETA-GLUCAN FOR IMMUNO-ENHANCEMENT AND/OR IMMUNO-BALANCING, AND FOR ADJUVANT USE | HIBSHMAN, SARAH GRACE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001994 | BETA-GLUCAN FOR IMMUNO-ENHANCEMENT AND/OR IMMUNO-BALANCING, AND FOR ADJUVANT USE | HIBSHMAN, SARAH GRACE | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18001994 | BETA-GLUCAN FOR IMMUNO-ENHANCEMENT AND/OR IMMUNO-BALANCING, AND FOR ADJUVANT USE | HIBSHMAN, SARAH GRACE | 1693 | §102§103§112 | Final Rejection | — | Pending | Dec 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial